Tianli Wang

Tianli Wang

Auto-generated profile, based on publicly available information

Tianli Wang

GSK, Waltham, Massachusetts

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
DDDiwakar Davar
Diwakar Davar
ZEZeynep Eroglu
Zeynep Eroglu
Mohammed MilhemMohammed Milhem
Mohammed Milhem
CBCarlos Becerra
Carlos Becerra
MGMARTIN Gutierrez
MARTIN Gutierrez
PLPatricia LoRusso
Patricia LoRusso
Purpose: Treatment options for patients with non–small cell lung cancer (NSCLC) who have progressed on anti–PD-(L)1 treatment are lacking. In preclinical models, blockade of the inhibitory immune receptor T-cell immunoglobulin and mucin-domain containing protein 3 (TIM-3) is associated with an antitumor response. AMBER (NCT02817633) part 2B assessed the safety and efficacy of cobolimab, an anti–TIM-3 humanized monoclonal antibody, plus PD-1 inhibitor dostarlimab in patients with locally advanced or metastatic NSCLC who had progressed on anti–PD-(L)1 treatment. Patients and Methods: Adult patients with anti–PD-(L)-1 treated locally advanced or metastatic NSCLC were included. Patients received cobolimab 100, 300, or 900 mg and dostarlimab 500 mg every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, patient withdrawal, investigator’s decision, or death. Endpoints included overall response rate, disease control rate, and safety. Post hoc biomarker assessments of pretreatment tumor biopsies were also assessed. Results: In total, 85 patients were enrolled and 84 received treatment. Treatment-emergent and treatment-related adverse events occurred in 98.8% and 52.4% of patients, respectively; no treatment-related deaths occurred. Across all three cobolimab doses, overall response rate was 8.3% (95% confidence interval, 3.4–16.4) and disease control rate was 21.4% (95% confidence interval, 13.2–31.7); both were highest in the 300 mg cohort (n = 41; 9.8% and 22.0%). Pretreatment TIM-3 expression was significantly greater in patients with partial or stable responses versus progressive disease. Conclusions: Cobolimab plus dostarlimab showed preliminary efficacy and tolerability in a subset of patients with locally advanced/metastatic NSCLC. See related article by Davar et al., p. XX

24 June 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
DDDiwakar Davar
Diwakar Davar
ZEZeynep Eroglu
Zeynep Eroglu
CLCasilda Llacer
Casilda Llacer
BPBrian Di Pace
Brian Di Pace
TWTianli Wang
Tianli Wang
ARAntoni Ribas
Antoni Ribas
Purpose: The phase I, open-label, multicenter AMBER study (NCT02817633) is evaluating cobolimab, an anti–T-cell immunoglobulin and mucin-domain containing protein-3 humanized mAb, as a monotherapy and combination therapy in patients with solid tumors. In this study, the safety and efficacy of cobolimab plus dostarlimab, a PD-1 inhibitor, in patients with locally advanced/metastatic melanoma who were either immunotherapy-naïve or had progressed on prior anti–PD-(L)1 therapy, are reported. Patients and Methods: Adults with adequate organ function and either immunotherapy-naïve (parts 1c/1e) or anti–PD-(L)1 relapsed or refractory (part 2A) melanoma were enrolled and received cobolimab 100, 300, or 900 mg and dostarlimab 500 mg every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, withdrawal of consent, or death (whichever occurred sooner). Endpoints included safety, tolerability, overall response rate, and disease control rate. Results: The current integrated analysis included 28 patients who received treatment in parts 1c/1e and 43 patients who received treatment in part 2A. Treatment-related serious adverse events were observed in 14.3% and 9.3% of patients in parts 1c/1e and 2A, respectively. The overall response rate (95% confidence interval) was 42.9% (24.5–62.8) and 4.7% (0.6–15.8) for patients in parts 1c/1e and 2A, respectively, and the disease control rate (95% confidence interval) was 53.6% (33.9–72.5; 1c/1e) and 20.9% (10.0–36.0; 2A). Conclusions: In this exploratory setting, cobolimab plus dostarlimab was well tolerated, with reported preliminary efficacy similar to other anti–T-cell immunoglobulin and mucin-domain containing protein-3 treatments in patients with locally advanced/metastatic melanoma. See related article by Davar et al., p. XX